Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology.
A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.
Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services.
While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
International Business Machines Corporation (IBM): Don't Abandon The Stock, Warns Jim Cramer
We recently published . International Business Machines Corporation (NYSE:IBM) is one of the stocks Jim Cramer recently discussed. International Business Machines Corporation (NYSE:IBM) is one of Cramer's favorite technology stocks. Throughout this year, the CNBC TV host has expressed optimism about the firm's CEO and the firm's consistency in winning contracts for its enterprise computing business. International Business Machines Corporation (NYSE:IBM)'s shares fell by 7.6% after the firm's latest earnings report saw software revenue of $7.39 billion miss analyst estimates of $7.43 billion. Cramer discussed the earnings report: 'Most of the news is good this morning, IBM. I still think not as bad, uh, Chipotle we have to talk about. Copyright: believeinme33 / 123RF Stock Photo Previously, he discussed potential future International Business Machines Corporation (NYSE:IBM) share price movement: 'Oh, I like IBM very much. I mentioned Ben Wright earlier. I think that Ben, he's really turned me on to this stock. We did a very positive piece about it. I think it goes, I'm going to say not much higher but creeping higher over time, and that's actually a great place to be. So I like IBM.' While we acknowledge the potential of IBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Northrop Grumman Corporation (NOC) Has Strong Worldwide Sales, Says Jim Cramer
We recently published . Northrop Grumman Corporation (NYSE:NOC) is one of the stocks Jim Cramer recently discussed. Northrop Grumman Corporation (NYSE:NOC) is a well-known defense contractor with a presence in the aircraft and missile industries. Its shares have gained 22% year-to-date, helped in large part by an 11% jump in July. Northrop Grumman Corporation (NYSE:NOC)'s stock soared due to its second-quarter earnings report, which saw the firm raise its midpoint full-year profit-per-share forecast to $25.20 from an earlier $25.15. The firm's $10.35 billion in revenue also beat analyst estimates of $10.07 billion. In his previous remarks about Northrop Grumman Corporation (NYSE:NOC), Cramer called the firm catastrophic after its Q1 results. This time, he struck a different tone: 'And Northrop Grumman, for worldwide sales. So we're seeing a lot of bifurcation in a lot of different industries.' Here's what Cramer said about Northrop Grumman Corporation (NYSE:NOC) after its Q1 results: 'Finally, there's Northrop Grumman, which was the dud of the day, reporting a severe top and bottom line miss for the first quarter, and cutting its full year earnings forecast pretty substantially. Now there's some important context here. Both the miss and the forecast cut were related to Northrop Grumman's next-generation B-21 bomber program. They're taking a hit on the higher cost as they try to ramp up production. Photo by NASA on Unsplash That said, even if you add that back, the impact from the B-21 charge, Northrop Grumman still would've missed the sales and earnings estimate. It just would've been a smaller disappointment. These Northrop Grumman results simply weren't up to snuff, so the stock had its worst day since 2008 today, falling $67 or nearly 13%. This one's now in the penalty box.' While we acknowledge the potential of NOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Dow Inc. (DOW): Good News About Industrial Economy Isn't Helping, Says Jim Cramer
We recently published . Dow Inc. (NYSE:DOW) is one of the stocks Jim Cramer recently discussed. Dow Inc. (NYSE:DOW) is one of the largest chemical companies in America. The firm's shares have lost 35% year-to-date, primarily on the back of a massive 26% selloff in April after President Trump announced his Liberation Day tariffs. Dow Inc. (NYSE:DOW)'s shares suffered another setback in July after they dipped by 17.5% after the firm's latest earnings report, which saw the firm guide third quarter sales at $10.2 billion, which was lower than analyst estimates of $10.6 billion. Dow Inc. (NYSE:DOW) also slashed its dividend, and here's what Cramer said about the firm after the disastrous earnings report: 'But then, Dow Chemicals, just, Dow, no longer Dow Chemicals. The chemicals are bad. The plastic is bad. So Jim Fitterling had to cut the dividend. I had said that this could happen. I didn't want it. But it's lower for longer, for three years, it's a very unusual negative cycle. And I've got to tell you, for all the good news we hear about the industrial economy, it's not helping. Previously, the CNBC TV host commented on Dow Inc. (NYSE:DOW)'s dividend yield: '9%, see I looked at that today. There were a bunch of guys who cut the price targets. I said to myself, wow, 9%… I have to take a pass because it means that there's something awry.' While we acknowledge the potential of DOW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
